Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant for CINV Prevention in MEC
NCT00337727Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2007
- Primary completion
- Oct 2008
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Jan 2007; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00337727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337727.